These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 23685175)
1. Synthesis and evaluation of novel orally active p53-MDM2 interaction inhibitors. Miyazaki M; Naito H; Sugimoto Y; Yoshida K; Kawato H; Okayama T; Shimizu H; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Shiose Y; Aonuma M; Soga T Bioorg Med Chem; 2013 Jul; 21(14):4319-31. PubMed ID: 23685175 [TBL] [Abstract][Full Text] [Related]
2. Discovery of DS-5272 as a promising candidate: A potent and orally active p53-MDM2 interaction inhibitor. Miyazaki M; Uoto K; Sugimoto Y; Naito H; Yoshida K; Okayama T; Kawato H; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Aonuma M; Soga T Bioorg Med Chem; 2015 May; 23(10):2360-7. PubMed ID: 25882531 [TBL] [Abstract][Full Text] [Related]
3. Lead optimization of novel p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold. Miyazaki M; Naito H; Sugimoto Y; Kawato H; Okayama T; Shimizu H; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Aonuma M; Soga T Bioorg Med Chem Lett; 2013 Feb; 23(3):728-32. PubMed ID: 23266121 [TBL] [Abstract][Full Text] [Related]
4. Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships. Miyazaki M; Kawato H; Naito H; Ikeda M; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Aonuma M; Soga T Bioorg Med Chem Lett; 2012 Oct; 22(20):6338-42. PubMed ID: 22995624 [TBL] [Abstract][Full Text] [Related]
5. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction. Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1. Wang W; Shangguan S; Qiu N; Hu C; Zhang L; Hu Y Bioorg Med Chem; 2013 Jun; 21(11):2879-85. PubMed ID: 23601819 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2. Wang W; Lv D; Qiu N; Zhang L; Hu C; Hu Y Bioorg Med Chem; 2013 Jun; 21(11):2886-94. PubMed ID: 23611770 [TBL] [Abstract][Full Text] [Related]
8. Rational design and binding mode duality of MDM2-p53 inhibitors. Gonzalez-Lopez de Turiso F; Sun D; Rew Y; Bartberger MD; Beck HP; Canon J; Chen A; Chow D; Correll TL; Huang X; Julian LD; Kayser F; Lo MC; Long AM; McMinn D; Oliner JD; Osgood T; Powers JP; Saiki AY; Schneider S; Shaffer P; Xiao SH; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Medina JC; Olson SH J Med Chem; 2013 May; 56(10):4053-70. PubMed ID: 23597064 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors. Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354 [TBL] [Abstract][Full Text] [Related]
10. Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction. Vaupel A; Bold G; De Pover A; Stachyra-Valat T; Lisztwan JH; Kallen J; Masuya K; Furet P Bioorg Med Chem Lett; 2014 May; 24(9):2110-4. PubMed ID: 24704029 [TBL] [Abstract][Full Text] [Related]
11. Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. Sun D; Li Z; Rew Y; Gribble M; Bartberger MD; Beck HP; Canon J; Chen A; Chen X; Chow D; Deignan J; Duquette J; Eksterowicz J; Fisher B; Fox BM; Fu J; Gonzalez AZ; Gonzalez-Lopez De Turiso F; Houze JB; Huang X; Jiang M; Jin L; Kayser F; Liu JJ; Lo MC; Long AM; Lucas B; McGee LR; McIntosh J; Mihalic J; Oliner JD; Osgood T; Peterson ML; Roveto P; Saiki AY; Shaffer P; Toteva M; Wang Y; Wang YC; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Yu M; Zhao X; Zhou J; Zhu J; Olson SH; Medina JC J Med Chem; 2014 Feb; 57(4):1454-72. PubMed ID: 24456472 [TBL] [Abstract][Full Text] [Related]
12. Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction. Gonzalez AZ; Eksterowicz J; Bartberger MD; Beck HP; Canon J; Chen A; Chow D; Duquette J; Fox BM; Fu J; Huang X; Houze JB; Jin L; Li Y; Li Z; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; McMinn DL; Oliner JD; Osgood T; Rew Y; Saiki AY; Shaffer P; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Olson SH; Medina JC; Sun D J Med Chem; 2014 Mar; 57(6):2472-88. PubMed ID: 24548297 [TBL] [Abstract][Full Text] [Related]
13. Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy. Li J; Wu Y; Guo Z; Zhuang C; Yao J; Dong G; Yu Z; Min X; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Miao Z; Zhang W Bioorg Med Chem Lett; 2014 Jun; 24(12):2648-50. PubMed ID: 24813735 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and CoMFA studies of N1-amino acid substituted 2,4,5-triphenyl imidazoline derivatives as p53-MDM2 binding inhibitors. Hu C; Dou X; Wu Y; Zhang L; Hu Y Bioorg Med Chem; 2012 Feb; 20(4):1417-24. PubMed ID: 22273545 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran-oxindole derivatives as potent p53-MDM2 inhibitors. Ji C; Wang S; Chen S; He S; Jiang Y; Miao Z; Li J; Sheng C Bioorg Med Chem; 2017 Oct; 25(20):5268-5277. PubMed ID: 28797774 [TBL] [Abstract][Full Text] [Related]
16. Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction. Wang Y; Zhu J; Liu JJ; Chen X; Mihalic J; Deignan J; Yu M; Sun D; Kayser F; McGee LR; Lo MC; Chen A; Zhou J; Ye Q; Huang X; Long AM; Yakowec P; Oliner JD; Olson SH; Medina JC Bioorg Med Chem Lett; 2014 Aug; 24(16):3782-5. PubMed ID: 25042256 [TBL] [Abstract][Full Text] [Related]
17. Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres. Gonzalez AZ; Li Z; Beck HP; Canon J; Chen A; Chow D; Duquette J; Eksterowicz J; Fox BM; Fu J; Huang X; Houze J; Jin L; Li Y; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; Oliner JD; Osgood T; Rew Y; Saiki AY; Shaffer P; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Olson SH; Sun D; Medina JC J Med Chem; 2014 Apr; 57(7):2963-88. PubMed ID: 24601644 [TBL] [Abstract][Full Text] [Related]
18. One-pot synthesis of spiro(indoline-3,4'-pyrazolo[3,4-b]pyridine)-5'-carbonitriles as p53-MDM2 interaction inhibitors. Ibrahim HS; Eldehna WM; Fallacara AL; Ahmed ER; Ghabbour HA; Elaasser MM; Botta M; Abou-Seri SM; Abdel-Aziz HA Future Med Chem; 2018 Dec; 10(24):2771-2789. PubMed ID: 30526032 [TBL] [Abstract][Full Text] [Related]
19. Structure-based design of novel inhibitors of the MDM2-p53 interaction. Rew Y; Sun D; Gonzalez-Lopez De Turiso F; Bartberger MD; Beck HP; Canon J; Chen A; Chow D; Deignan J; Fox BM; Gustin D; Huang X; Jiang M; Jiao X; Jin L; Kayser F; Kopecky DJ; Li Y; Lo MC; Long AM; Michelsen K; Oliner JD; Osgood T; Ragains M; Saiki AY; Schneider S; Toteva M; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Medina JC; Olson SH J Med Chem; 2012 Jun; 55(11):4936-54. PubMed ID: 22524527 [TBL] [Abstract][Full Text] [Related]